#Respiratory Syncytial Virus (RSV) Therapeutics Market Research

[soumyafwr]

Respiratory Syncytial Virus (RSV) Therapeutics Market

[credenceresearchdotblog]

The Prenatal Vitamin Supplement Market is projected to grow from USD 563.41 million in 2023 to an estimated USD 1,126.26 million by 2032, registering a compound annual growth rate (CAGR) of 8.00% from 2024 to 2032.The Prenatal Vitamin Supplement Market is projected to grow from USD 563.41 million in 2023 to an estimated USD 1,126.26 million by 2032, registering a compound annual growth rate (CAGR) of 8.00% from 2024 to 2032.The global respiratory tract infection treatment market has experienced significant growth in recent years due to the rising prevalence of respiratory illnesses, increasing awareness about the importance of early diagnosis and treatment, and the ongoing demand for novel therapeutic options. Respiratory tract infections (RTIs), both upper and lower, remain some of the most common infectious diseases worldwide. They range from mild conditions such as the common cold to more severe diseases like pneumonia, bronchitis, and even life-threatening conditions caused by viruses such as influenza and respiratory syncytial virus (RSV).

Browse the full report at https://www.credenceresearch.com/report/prenatal-vitamin-supplements-market

Market Dynamics

Rising Prevalence of Respiratory Infections One of the major drivers of the market is the increasing incidence of respiratory infections globally. Factors such as growing urbanization, air pollution, and climate change have contributed to the rise in respiratory diseases. Furthermore, the global COVID-19 pandemic has increased awareness about the seriousness of respiratory infections, thus driving the demand for preventive measures, diagnostics, and treatments.

According to the World Health Organization (WHO), lower respiratory tract infections like pneumonia remain a leading cause of mortality in both children and adults worldwide. This has emphasized the need for effective treatment options and boosted investment in research and development for innovative therapies.

Advancements in Treatment Modalities The market for respiratory tract infection treatment has seen significant advancements in both pharmacological and non-pharmacological interventions. Antiviral drugs, antibiotics, and immunotherapies are widely used to treat various respiratory infections. Newer treatment modalities, such as monoclonal antibodies and vaccines targeting specific respiratory pathogens, have expanded the scope of therapeutic options available to healthcare providers.

For instance, vaccines against respiratory infections like pneumococcal pneumonia and influenza are essential preventive measures that have become more widespread, especially in high-risk populations. Moreover, with the rise of antibiotic resistance, there has been a growing focus on developing new classes of antibiotics and alternative therapies, such as bacteriophage therapy and host-directed therapies.

Increasing Research & Development Activities Pharmaceutical companies and research institutions are investing heavily in the development of novel therapies and drugs to treat respiratory infections. The growing focus on personalized medicine, precision diagnostics, and targeted therapies is expected to further enhance treatment outcomes. Additionally, the development of combination therapies that target multiple aspects of the infection process (e.g., viral replication and immune response) has shown promise in improving patient recovery.

A key trend in research is the use of advanced biotechnological approaches to create therapies that can modulate the immune response to respiratory pathogens, rather than simply targeting the pathogens themselves. This approach is especially important for conditions like severe influenza and COVID-19, where an overactive immune response can lead to complications such as acute respiratory distress syndrome (ARDS).

Market Challenges

Antibiotic Resistance One of the major challenges facing the respiratory tract infection treatment market is the increasing rate of antimicrobial resistance (AMR). Overuse and misuse of antibiotics have led to the emergence of resistant strains of bacteria, making it difficult to treat infections effectively. This has prompted a significant need for new antibiotics and alternative treatments. Pharmaceutical companies face the dual challenge of developing novel antibiotics while ensuring their responsible use to prevent further resistance.

High Treatment Costs The cost of treatment, especially for more severe infections requiring hospitalization, can be prohibitive for many patients, particularly in low- and middle-income countries. While the availability of generic drugs helps to reduce costs, advanced therapies like biologics and monoclonal antibodies can be expensive, limiting access for many patients.

Regulatory Hurdles Regulatory approval for new drugs and therapies remains a lengthy and expensive process. Stringent regulations and the need for extensive clinical trials to demonstrate safety and efficacy can delay the introduction of new treatments to the market. Additionally, the varying regulatory frameworks across different regions can create obstacles for companies aiming to launch their products globally.

Future Outlook and Opportunities

The respiratory tract infection treatment market is expected to continue its upward trajectory, driven by several factors. The growing geriatric population, who are more susceptible to respiratory infections, will contribute to increased demand for treatment options. Additionally, the ongoing development of vaccines and antiviral therapies for emerging viral pathogens like SARS-CoV-2 and RSV is likely to further boost market growth.

Telemedicine and digital health solutions are emerging as promising tools in the management of respiratory infections, offering remote consultation and monitoring, particularly in rural or underserved areas. Moreover, partnerships between pharmaceutical companies and academic institutions are expected to accelerate the discovery of novel treatments and diagnostics.

Segments

Based on product

Capsules/Tablets

Powder

Gummy

Liquid

Others

Based on nature

Organic

Conventional

Based on distribution channel

Supermarkets & Hypermarkets

Pharmacy & Drug Stores

Online

Others

Based on region

North America

U.S.

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Spain

Rest of Europe

Asia Pacific

China

Japan

India

South Korea

South-east Asia

Rest of Asia Pacific

Latin America

Brazil

Argentina

Rest of Latin America

Middle East & Africa

GCC Countries

South Africa

Rest of the Middle East and Africa

Browse the full report at https://www.credenceresearch.com/report/prenatal-vitamin-supplements-market

About Us:

Credence Research is committed to employee well-being and productivity. Following the COVID-19 pandemic, we have implemented a permanent work-from-home policy for all employees.

Contact:

Credence Research

Please contact us at +91 6232 49 3207

Email: sales@credenceresearch.com

Website: www.credenceresearch.com

[priyanshisingh]

POC Molecular Diagnostics Market 2022 | Growth Strategies, Opportunity, Challenges, Rising Trends and Revenue Analysis 2030

The latest market report published by Credence Research, Inc. “Global POC Molecular Diagnostics Market: Growth, Future Prospects, and Competitive Analysis, 2022 – 2030. The global demand for POC molecular diagnostics was valued at USD 6.9 Billion in 2022 and is expected to reach USD 8.6 Billion in 2030, growing at a CAGR of 3.3% between 2023 and 2030.

Point-of-Care (POC) Molecular Diagnostic solutions have become pivotal. These tools bridge the gap between rapid diagnostics and precision medicine, offering clinicians timely, actionable insights. This article provides a holistic perspective on the POC molecular diagnostic market, its current dynamics, and its potential trajectory.

POC Molecular Diagnostics Market Dynamics refer to the ever-evolving landscape of point-of-care molecular diagnostics, a field that combines the power of molecular biology with rapid testing at the patient's bedside. This market is driven by several key factors, including advancements in technology and growing demand for personalized medicine. The integration of portable devices and miniaturized laboratory equipment has revolutionized healthcare delivery, allowing for quick and accurate diagnosis of diseases like HIV, tuberculosis, influenza, and genetic disorders. With POC molecular diagnostics paving the way towards precision medicine, patients can receive targeted treatments based on their unique genetic makeup. This emerging market also benefits from increased accessibility as it eliminates the need for time-consuming laboratory processes and enables remote testing in resource-limited settings.

Point-of-Care (POC) Molecular Diagnostics market encompasses the sector of medical testing that employs molecular techniques to detect and diagnose conditions at or near the location of patient care. These diagnostics are pivotal for quick turn-around results, often enabling physicians to make immediate and informed decisions about patient care. The convenience and speed of POC molecular diagnostics are propelling their adoption, especially in settings like urgent care clinics, hospitals, and even remote field clinics. As technology has advanced, these tests have become more accurate, portable, and user-friendly, further driving their demand.

The market's growth is also influenced by the rising prevalence of infectious diseases, increased awareness for early detection, and the constant need for decentralized diagnostic solutions. Continuous research and development have led to the introduction of advanced products, leveraging technologies like PCR (polymerase chain reaction) and next-generation sequencing, adapted for POC settings. Given the current trajectory and the emphasis on personalized medicine and rapid diagnostics, the POC Molecular Diagnostics market is poised for significant growth in the foreseeable future.

Key Players in the Market

Roche: Recognized for their cutting-edge platforms like the Cobas Liat.

Abbott: Renowned for their ID NOW series.

Biomerieux: Delivering comprehensive solutions through platforms like the BioFire FilmArray.

Applications: Beyond Infectious Diseases

Though infectious diseases remain the most common application, the utility of POC molecular diagnostics extends to:

Oncology: Identifying tumor markers for precise cancer treatment.

Pharmacogenomics: Guiding therapeutic decisions based on patient genetics.

Browse 228 pages report POC Molecular Diagnostics Market By Technology (PCR-based, Genetic Sequencing-based, Hybridization-based, Microarray-based) By Application Type (Infectious Diseases, HIV POC, Clostridium difficile POC, HBV POC, Pneumonia or Streptococcus associated infections, Respiratory syncytial virus (RSV) POC, HPV POC)  - Growth, Future Prospects & Competitive Analysis, 2016 – 2030)- https://www.credenceresearch.com/report/poc-molecular-diagnostics-market

 Growth Drivers & Challenges:

Outbreak of new diseases: Recent pandemics have underlined the need for rapid diagnostic tools.

Technological advancements: Innovations, especially in PCR and isothermal amplification, have transformed diagnostics.

Government initiatives: Increasing funding and support for swift and accurate diagnostics.

Anticipated Market Hurdles:

High costs: The advanced technology can be expensive, potentially limiting widespread adoption.

Requirement for skilled personnel: Though designed to be user-friendly, some equipment demands specialized training.

Future Directions & Potential

The future of POC molecular diagnostics looks promising with:

Integration of AI: Predictive analytics can further enhance accuracy and speed.

Wearable diagnostics: The next frontier might be wearables that continually monitor and diagnose in real-time.

Conclusion

The Point-of-Care Molecular Diagnostic market is poised for significant growth, driven by technological advancements, rising disease outbreaks, and increasing healthcare demands globally. As the healthcare paradigm shifts towards precision and rapid diagnostics, POC molecular tools are set to play a more prominent role in shaping global health outcomes.

Why to Buy This Report-

The report provides a qualitative as well as quantitative analysis of the global POC Molecular Diagnostics Market by segments, current trends, drivers, restraints, opportunities, challenges, and market dynamics with the historical period from 2016-2020, the base year- 2021, and the projection period 2022-2028.

The report includes information on the competitive landscape, such as how the market's top competitors operate at the global, regional, and country levels.

Major nations in each region with their import/export statistics

The global POC Molecular Diagnostics Market report also includes the analysis of the market at a global, regional, and country-level along with key market trends, major players analysis, market growth strategies, and key application areas.

Browse Full Report: https://www.credenceresearch.com/report/poc-molecular-diagnostics-market

Visit: https://www.credenceresearch.com/

Related Report: https://www.credenceresearch.com/report/automatic-veterinary-biochemistry-analyzer-market

Related Report: https://www.credenceresearch.com/report/automated-and-rapid-microbiological-tests-market

Browse Our Blog: https://www.linkedin.com/pulse/poc-molecular-diagnostics-market-size-worth-usd-86-billion-singh

Browse Our Blog: https://tealfeed.com/poc-molecular-diagnostics-market-size-worth-gywps

About Us -

Credence Research is a viable intelligence and market research platform that provides quantitative B2B research to more than 10,000 clients worldwide and is built on the Give principle. The company is a market research and consulting firm serving governments, non-legislative associations, non-profit organizations, and various organizations worldwide. We help our clients improve their execution in a lasting way and understand their most imperative objectives. For nearly a century, we’ve built a company well-prepared for this task.

Contact Us:

Office No 3 Second Floor, Abhilasha Bhawan, Pinto Park, Gwalior [M.P] 474005 India

[healthcare-market]

Respiratory Syncytial Virus Therapeutics Market Demand, Insights and Forecast up to 2025

The global respiratory syncytial virus therapeutics market was valued at approximately US$ 820.0 Mn in 2016 is projected to expand at a CAGR of more than 11.0% from 2017 to 2025, according to a new report published by Transparency Market Research (TMR) titled “Respiratory Syncytial Virus (RSV) Therapeutics Market – Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2017–2025”. The report suggests that the rise in unmet medical needs within the antiviral therapy to treat RSV infection and the rise in prevalence of RSV infection globally is likely to boost the demand for anti RSV infection drugs during the forecast period. North America and Western Europe are likely to dominate the global respiratory syncytial virus therapeutics market due to increasing awareness and the focus of key players on the development of new drugs and vaccine in the market in these regions. Demand for new diagnostic assay and increasing research activity in emerging markets such as China and Japan are likely to boost the Asia Pacific respiratory syncytial virus therapeutics market at a CAGR of 11.8% from 2017 to 2025.

Request a PDF Brochure - https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=42701

High Price of Monoclonal Antibody Injection Hampering the Market

High price does little except leave the most vulnerable children unprotected. Human monoclonal antibodies prices have risen from single digits to triple digits in the last two decades. The cost of an antibody injection is becoming unaffordable in under-developed countries, due to a lack of price transparency. This is a major factor restraining the market. For example, the estimated average 2016-2017 seasonal cost of Palivizumab antibody injection (Synagis) to prevent RSV disease ranged from US$ 2600 to US$ 3500 in seasonal time. However, there is no approved vaccine to treat RSV infection. Therefore, still to some extent it is using in the developing and developed countries.

Request a Sample of Respiratory Syncytial Virus (RSV) Treatment Market: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=42701

Ribavirin Drug to Lose Market Share

The report offers detailed segmentation of global respiratory syncytial virus (RSV) therapeutics market based on drugs type, dosage form, and distribution channel. Among the drugs type studied, the palivizumab segment is estimated to account for a leading share of the global market during the forecast period. This is due to the unavailability of approved drugs and vaccine in the market and moreover, several studies indicate that the efficacy rate of palivizumab antibody is high and reduces the rate of hospitalization after usage. The ribavirin drug segment is anticipated to lose market share during the forecast period, and is expected to hold a share of about 23.0% by 2025, a decline from about 24% share held in 2016. Lack of efficacy of the drugs and resistance against RSV infection are factors that are likely to hamper this segment.

Request for Analysis of COVID19 Impact on Respiratory Syncytial Virus (RSV) Treatment Market - https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=42701

Injectable and Oral Dosage Form: Top Dosage Form to Prevent or Treat RSV Infection

In terms of dosage form, the injectable segment is projected to hold a dominant share of the global respiratory syncytial virus (RSV) therapeutics market during the forecast period. The segment is likely to expand at a CAGR more than 12.0% from 2017 to 2025. Major factors responsible for the dominance of this segment is to provide instants response to treat or prevent RSV infection. For example, AstraZeneca, has developed a monoclonal antibody, called SYNAGIS, to prevent severe RSV infection, which is available in the injectable form. The advantage of this injection is that it instantly boosts the immune system to combat against the infection. The oral segment accounted for more than 31.0% share of the global respiratory syncytial virus (RSV) therapeutics market, in terms of value, in 2016. It is anticipated to witness expansion at a substantial growth rate during the forecast period. The market share held by the segment is likely to reach 32.1% of the market by 2025.

Enquiry before Buying Respiratory Syncytial Virus (RSV) Treatment Market Report - https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=42701

North America to Register Exponential Growth and Offer Huge Incremental Opportunity

In terms of value, North America held a major share of the global respiratory syncytial virus (RSV) therapeutics market in 2016. This is due to the high level of research activity in the U.S.. Furthermore, presence of several key players such as NOVAVAX, Inc, Gilead Sciences, and Sanofi Pasteur has led to increased investment in research and development of anti RSV drugs. Thus, presence of these players are projected to propel the syncytial virus (RSV) therapeutics market in North America at a rapid pace during the forecast period Pharmaceutical research and development spending in emerging markets such as China and India is rising, which is also fueling the expansion of the Asia Pacific respiratory syncytial virus (RSV) therapeutics market. Regaining economic growth in Latin American markets such as Brazil is boosting research and development activity, spending is increasing in diagnosis and treatment of RSV infection in this region. This factor is likely to propel the Latin America respiratory syncytial virus (RSV) therapeutics market at a CAGR of 7.0% from 2017 to 2025.

Key Players such as AstraZeneca plc, and AbbVie, Inc. are Likely to Lead the Global Respiratory Syncytial Virus (RSV) Therapeutics Market

The report also provides profiles of leading players operating in the global respiratory syncytial virus (RSV) therapeutics market. These include F. Hoffmann-La Roche Ltd., Merck & Co., Inc., Valeant Pharmaceuticals International, Inc., GlaxoSmithKline plc. ReViral Ltd., Gilead Sciences, Inc., Teva Pharmaceutical Industries Ltd. and MEDIVIR AB. Expansion of anti RSV drugs and vaccines-based products portfolio through improving existing drugs and developing new drug molecules is a key strategy adopted by several key players, recent developing drugs such as CT-P14 a bio similar products of palivizumab is developing by Celltrion Inc. and other key players reflect these strategies.

More Trending Reports by Transparency Market Research:

About Us Section:

Transparency Market Research is a global market intelligence company, providing global business information reports and services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insight for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants, use proprietary data sources and various tools and techniques to gather, and analyse information. Now avail flexible Research Subscriptions, and access Research multi-format through downloadable databooks, infographics, charts, interactive playbook for data visualization and full reports through MarketNgage, the unified market intelligence engine. Sign Up for a 7 day free trial!

Contact Us

Rohit Bhisey Transparency Market Research, 90 State Street, Suite 700, Albany, NY 12207 Tel: +1-518-618-1030 USA – Canada Toll Free: 866-552-3453 Email: sales@transparencymarketresearch.com

Website: https://www.transparencymarketresearch.com/

[abhigmi]

Europe Antiviral Drugs Market Revenue to Reach $ 8.7 Billion by 2027

According to an estimate, Europe antiviral drugs market size will surpass USD 8.7 billion by 2027. Rising cases of viral infection, including hepatitis, coronavirus, AIDS and respiratory syncytial virus (RSV) infection will underscore Europe antiviral drugs market value. Soaring geriatric demographics will further augment the product adoption. Prominently, elderly population suffering from hypertension, diabetes and CVD are more prone to coronavirus.

An upsurge in the number of drug approvals will augur well for the industry size expansion. The application of anti-viral drugs has played a pivotal role in reducing infection and viral load. Moreover, rising marketing authorization for COVID-19 prescription drugs will further the market presence of drugs. Russia, for instance, gave a green signal for the first COVID-19 drug in September 2020 for sale in pharmacies.

Get sample copy of this research report @ https://www.graphicalresearch.com/request/1737/sample

Expanding foothold of reverse transcriptase inhibitors following the rise in HIV population will bolster the manufacturing of antiviral drugs in the U.K., Italy, Germany and France. Moreover, rise in FDA approvals has further added impetus towards the product portfolio expansion of the drug. The reverse transcriptase inhibitors segment witnessed over 40% market share in 2020 and will thrive with increasing footprint across the end-use applications.

End-users are expected to show increased traction towards branded drugs as they have original drug class which are manufactured and developed through original pharmaceutical company. Besides, bullish demand for branded drugs and an upsurge in research and development activities have come in the backdrop of increased efficacy and specificity.

A meteoric rise in hepatitis cases has prompted the manufacturers to up the production of antiviral drugs. According to the WHO, hepatitis incidence rate among the EU members stands at 8.7 per 100,000.  Europe antiviral drugs market revenue from the hepatitis segment surpassed USD 2 billion in 2020 and will grow owing to rise in drug approval across the region.

With a spike in geriatric population across the region, industry participants are poised to inject funds in the landscape. According to the Eurostat, over 20% of the EU-27 population are aged 65 years or over. The market share from the geriatric segment in Europe will grow at a considerable rate by 2027.

The U.K. is likely to come up as a happy hunting ground in the wake of expansion of healthcare facilities and presence of large patient pool. Prominently, thriving R&D activities and presence of leading companies will underscore the business outlook. Robust approval of drugs and rising drug trial will pan well for industry participants vying to expand their portfolios. Specifically, the U.K. confirmed the roll out of new trial in May 2020 focusing on COVID-19 patients.

Stakeholders will expand their presence in Germany on the heels of use of anti-viral medicines for the treatment of infectious diseases, including hepatitis and coronavirus. Notably, surge in baby boomer population has further augmented the demand for anti-viral therapeutics. The American Association of Retired Persons claims that Germany is among the five super-aged societies in the globe. The number of people aged 65 and older is forecast to be pegged at 24 million by 2050 in Germany.

Request for customization @ https://www.graphicalresearch.com/request/1737/customize-this-report

 Europe antiviral drugs market players in the landscape are GlaxoSmithKline, plc, AstraZeneca, Johnson & Johnson, Gilead Science and Merck & Co., among others. These leading companies will further their product lines and up their focus on mergers & acquisitions. Illustratively, Gilead was approached by AstraZeneca for a merger in June 2020.

Table of Contents (ToC) of the report:

Chapter 1   Methodology

1.1    Market definitions

1.2    Forecast assumptions

1.3    Data sources

1.3.1    Secondary

1.3.1.1    Paid sources

1.3.1.2    Unpaid sources

1.3.2    Primary

Chapter 2   Market Summary

2.1    Europe antiviral drugs market summary, 2016 – 2027

2.1.1    Country trends

2.1.2    Drug class trends

2.1.3    Indication trends

2.1.4    Type trends

2.1.5    Age group trends

Chapter 3   Market Analysis

3.1    Industry segmentation

3.2    Industry outlook, 2016 - 2027

3.3    Major factor analysis

3.3.1    Growth drivers

3.3.1.1    Increasing prevalence of viral infection

3.3.1.2    Presence of large geriatric population

3.3.1.3    Increasing research and development activities in the field of Anti-viral drugs

3.3.2    Industry pitfalls and challenges

3.3.2.1    Rising awareness about preventive drug treatment

3.3.2.2    Presence of generics

3.4    Analysis of COVID-19 impact on the industry

3.5    Porter’s analysis

3.6    Competitive review, 2020

3.7    PEST analysis

Browse complete Table of Contents (ToC) of this research report @ https://www.graphicalresearch.com/table-of-content/1737/europe-antiviral-drugs-market

 About Graphical Research:

Graphical Research is a business research firm that provides industry insights, market forecast and strategic inputs through granular research reports and advisory services. We publish targeted research reports with an aim to address varied customer needs, from market penetration and entry strategies to portfolio management and strategic outlook. We understand that business requirements are unique: our syndicate reports are designed to ensure relevance for industry participants across the value chain. We also provide custom reports that are tailored to the exact needs of the customer, with dedicated analyst support across the purchase lifecycle.

Contact Us:

Parikhit B.

Corporate Sales,

Graphical Research

Phone: 1-800-986-6917

Email: sales@graphicalresearch.com

Web: https://www.graphicalresearch.com

[nitasonwane]

Respiratory Syncytial Virus Therapeutics Market Demand, Trends, Growth, to 2027

The global respiratory syncytial virus (RSV) therapeutics market size is estimated to showcase potential growth owing to its increasing adoption against the prevention and treatment of the disease, observes Fortune Business Insights™ in an upcoming report, titled, “Respiratory Syncytial Virus (RSV) Therapeutics Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Prophylaxis and Treatment), By End-user (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) and Regional Forecast, 2020-2027.” The respiratory syncytial virus (RSV) therapeutics market stood at USD 1,111.3 million in 2019. It is projected to grow from USD 609.2 million in 2020 to USD 4,003.4 million in 2027 at a CAGR of 30.9% in the forecast period.

For More Questions, Talk with Respiratory Syncytial Virus (RSV) Therapeutics Industry Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/respiratory-syncytial-virus-rsv-therapeutics-market-104668

High Production Scale to Hinder Growth Opportunities in Global Pharmaceutical Space

The COVID-19 contagion is expected to drive the global pharmaceutical industry. Enterprises across the world along with governments from several nations are contributing to the development and distribution of the vaccine. However, the scale at which the production is assumed to take place is a major challenge for most of the renowned players. At Fortune Business Insights™, we are providing actionable insights by closely studying multiple aspects of the current scenario. We are also offering firsthand information on various market trends through our comprehensive research reports.

New Product Launches from Key Players Helped Prophylaxis Segment Hold Largest Share In 2019

Based on drug class, the prophylaxis segment led the market with the largest share in 2019. Potential approvals and launch of maternal vaccines by companies including Pfizer and GSK are estimated to help the segment further dominate the market during the forecast timeframe. Based on end-user, the hospital pharmacy segment dominated the global market owing to the high demand for healthcare professionals for the existing treatment and prevention options.

[sapanas]

RSV Diagnostics Market 2021: Gross Margin Analysis, Global Overview, Emerging Trends, Leading Growth Drivers, Future Estimation And Industry Outlook 2023

RSV Diagnostics Market Highlights

The latest report by Market Research Future (MRFR) states that the Respiratory Syncytial Virus (RSV) market is all set to gain substantial traction by accruing gigantic revenues by 2023. In addition, it is on track to surge at a CAGR of 10.4 % during the forecast period (2018–2023).

RSV Diagnostics Market Drivers and Top Restraints

The document named “Reducing Neonatal Mortality and Morbidity in Latin America And the Caribbean, An Interagency Strategic Consensus” states that almost 400,000 children under the age of five die due to infections that could have been prevented. This has attracted the focus of various health agencies that are striving to get a hold of the issue. For instance, Latin American Center for Perinatology and Pan America Health Organization (PAHO) have diverted their focus in the direction of educating the parents to fight against possible infections, promoting the growth of the RSV diagnostics market in the process.

The rising incidence rate of respiratory infections has done wonders for the market and is bound to surge at a significant rate in the coming years. with the growth in the incidences of chronic diseases around the world, there is bound to be an increase in the case of respiratory infections. This is going to have a definite positive impact on the demand for testing of infectious diseases like RSV. The deaths among neonates owing to these infections can be prevented when timely diagnosis and subsequent treatment is provided. Thus, the growing awareness regarding this factor is set to enhance the growth of the RSV diagnostics market in the years ahead.

The boost in the number of product launches across the globe will be one of the primary reasons fueling the growth of the respiratory syncytial virus diagnostics market in the forthcoming years. On that note, various diagnostics companies are keen on expanding their revenue with the development and introduction of the latest RSV diagnostics products in the market. These sophisticated diagnostic products are known to be highly efficient and reduce the time needed for the diagnosis.

The Rising Number of OEMs to be the Key Trend in the Global Market

The growth in the number of original equipment manufacturers (OEMs) is on its way to become a popular trend in the worldwide RSV diagnostics market in the near future. OEMs like Thermo Fisher Scientific and Sekisui Diagnostics are one of the leading manufacturers that offer RSV diagnostics.

There has been a rise in the number of combination products like drug delivery and smart devices, which is prompting the OEMs to work in conjunction with the contract manufacturing organizations (CMOs), making way for a number of new companies to gain entry into the market. As a result, there has been an increase in the product range required for diagnosing RSV.

RSV Diagnostics Market Segmentation

The global RSV diagnostics market has been segmented based on product, method, and end-user.

Depending on the type of product, the market has been classified into kits and assays, instruments, and other products.

Method-wise, the global RSV diagnostics market has been considered for molecular diagnostics, rapid antigen detection test, gel microdroplets, flow cytometry, and others. Furthermore, the rapid antigen detection tests are sub-segmented into enzyme-linked immunosorbent assays, immunofluorescence assays, and other rapid antigen detection tests. The other type of rapid antigen detection tests can be segmented into chromatographic immunoassays and optical immunoassays.

The end-users mentioned in the report include hospitals and clinics, clinical laboratories, home care, and others.

RSV Diagnostics Market Regional Outlook

The global RSV diagnostics market is segmented into the regional markets of the Americas, Asia Pacific, Europe, as well as the Middle East & Africa.

The Americas will be the most lucrative market for RSV diagnostics on account of the rising incidences of RSV, growing healthcare expenditure and technological advancements in molecular diagnostics. As per the Centers for Disease Control and Prevention, over 57,000 children younger than five years old are hospitalized owing to RSV infection every year, in the United States (U.S). In order to bring down this abysmal number, various initiatives and programs are being introduced in the region, which means that the market will be doing excellent business in the region in the years to come.

Meanwhile, Europe has landed the second spot in the global RSV diagnostics market, with factors like increasing automation in vitro diagnostics, rising occurrence of RSV diseases, and surging funding offered by the government backing the said growth. Considering the current status of the region, the data furnished by the University of Oxford states that more than 30,000 babies and children less than five years of age are expected to be hospitalized every year owing to RSV.

The RSV diagnostics market in Asia Pacific can be broken down into smaller markets in the countries of India, Japan, China, Republic of Korea, Australia and the rest of the region. The regional market is touted to be the fastest-growing globally as a result of the rise in the infectious disease which includes the RSV infection. Also, the increasing healthcare expenditure coupled with the surge in the demand for RSV disease diagnosis has taken the market to higher levels in the past few years. In addition, countries like India, China, and Japan are deemed to be growing at the fastest rate in the region with the expanding healthcare systems along with the growing government initiatives backing up these markets.

Showcasing a rather sluggish growth rate in the global market is the region of the Middle East and Africa, which despite various restraints holds immense potential. The market shows promise, with the support of various factors including the increasing awareness and high investments by private industry participants combined with the increasing incidences of RSV in children in the region.

Get Premium Research Report, Inclusive of COVID-19 Impact Analysis, Find more information @ https://www.marketresearchfuture.com/reports/rsv-diagnostics-market-6217

RSV Diagnostics Market Key Vendors

Bio-Rad Laboratories Inc., Abbott, F. Hoffman-La Roche Ltd., Danaher Corporation, Quest Diagnostics, Biocartis, Luminex, Hologic, Fast Track Diagnostics, Biomerieux, Becton, Dickinson, and Company (BD), Alere, Inc., Quidel Corporation, Thermo Fisher Scientific are among some of the top most companies in the RSV diagnostics market.

RSV Diagnostics Industry Latest News

May 2019: SpeeDx Pty. Ltd. has gotten the clearance from the Australian Therapeutic Goods Administration (TGA) of their PlexPCR RespiVirus test. It makes use of the PlexPCR technology for detecting 11 types of pathogens known for causing viral respiratory-illnesses. In addition, this test also lets the laboratories process a greater number of samples in a limited period of shift compared to a conventional in-house test.

[soumyafwr]

https://chatterchat.com/read-blog/79256_global-respiratory-syncytial-virus-rsv-therapeutics-market-size-share-and-foreca.html

Respiratory Syncytial Virus (RSV) Therapeutics Market 

[factmrresearch1]

U.S. NON-ONCOLOGY BIOPHARMACEUTICALS MARKET

Biologics can be defined as molecules derived from living cells such as microorganisms, plants or animal cells and used in the treatment, diagnosis or prevention of diseases. Most of the biologic molecules are very large, complex molecules or mixture of molecules.

Biopharmaceuticals are part of a wider category of therapeutic agents called biologics. Biopharmaceuticals are the substances developed in living systems with the help of biotechnology and are used in therapeutic and diagnostic applications. Non-oncology biopharmaceuticals are the drugs that are used in the treatment of various diseases rather than cancer such as rheumatoid arthritis, psoriatic arthritis, multiple sclerosis, hemophilia, age-related macular degeneration, osteoporosis, and others.

Increasing launches, approvals, and robust pipeline of novel biopharmaceuticals for non-oncology indications

Frequent approvals, launches, and robust pipeline of novel non-oncology biopharmaceuticals for various indications in the U.S. market is expected to significantly support the U.S. non-oncology biopharmaceuticals market growth.

For instance, in September 2018, Eli Lilly and Company received the U.S. Food and Drug Administration (FDA) approval for its Emgality (galcanezumab-gnlm) 120 mg injection, for the preventive treatment of migraine in adults.

In February 2018, Novartis announced that the U.S. Food and Drug Administration (FDA) approved a label update for its Cosentyx (secukinumab), the first interleukin-17A (IL-17A) inhibitor approved to treat moderate-to-severe plaque psoriasis.

In July 2018, Amgen Inc. and UCB Inc. resubmitted the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for EVENITY (romosozumab), an investigational monoclonal antibody for the treatment of osteoporosis in postmenopausal women at high risk of fracture.

The U.S. non-oncology biopharmaceuticals market size was valued at US$ 116.0 Bn in 2018 and is expected to witness a CAGR of 10.2% during the forecast period (2018 – 2026).

Figure 1. U.S. Non-oncology Biopharmaceuticals Market Share (%), By Product Type, 2018-2026

                        Source: Coherent Market Insights Analysis (2018)

Increasing mergers and collaborations among key players for development of novel non-oncology biopharmaceuticals is expected to support the market growth

Key players in the market are involved in strategic mergers and collaborations for the development of new biopharmaceutical products and to market them in the U.S. Such strategic mergers and collaborations between key players is expected to support the development of novel products, which in turn is expected to fuel the U.S. non-oncology biopharmaceuticals market growth over the forecast period.

For instance, in 2017, Sanofi S.A. and its vaccines business unit Sanofi Pasteur collaborated with MedImmune, the global biologics research and development arm of AstraZeneca Plc., for the development and commercialization of a monoclonal antibody, namely MEDI8897, for the prevention of Respiratory Syncytial Virus (RSV) associated illness in newborns and infants.

High price of branded biologic products is expected to be a major factor negatively affecting its adoption

According to the report published by the Association for Accessible Medicines in 2018, the annual treatment with Humira comes with a list price of US$ 38,000, and according to the report published by I-Mak.org, between 2012 and 2016, the average spending on Humira per person in U.S. increased from US$ 16,000 to US$ 33,000.

Table 1. Revenue of Top Non-oncology Biopharmaceutical Brands in the U.S.

Source: Coherent Market Insights Analysis (2018)

Market Opportunity

In the recent past, various blockbuster biologics such as Humira and Remicade lost patent in the U.S. market. Furthermore, various other high revenue generating biologics are expected to lose their patents in the near future.

Loss of patent in the U.S. market offers lucrative opportunity to other players for development of its biosimilars. Hence, key players in the market are focused on launch and development of biosimilars of biologic products in the market at affordable price.

For instance, in 2017, Merck & Co., Inc. launched RENFLEXIS (infliximab-abda), a biosimilar of the originator biologic medicine Remicade (infliximab) by Janssen Biotech, Inc. As per the company, RENFLEXIS is introduced in the U.S. at a list price (wholesaler acquisition cost) of US$ 753.39, representing a 35% discount to the current list price of Remicade, which is its reference product.

Market Challenges

High R&D Investments: Developing an IV/injectable biopharmaceutical requires sophisticated infrastructure, skilled scientists, and significant resource investment. Development of a biopharmaceutical product requires extensive clinical research and multiple phases of trials, which is a lengthy and expensive process. These factors are significant barriers for the new players to enter the market.

Sales and Marketing: The U.S. non-oncology biopharmaceuticals market has established market players with strong sales and marketing team. Presence of such strong players in the country creates a big challenge for new players to enter the market and to sustain against such big players.

Physician Acceptance: Physician acceptance of substitutes for well-established products may be a challenge, particularly among indications for which numerous products are available and substitutes do not exhibit high/ better safety profile and/or lower cost.

Key players operating in the U.S. non-oncology biopharmaceuticals market include Sanofi S.A., Pfizer, Inc., Johnson & Johnson, Novartis International AG, Amgen, Inc., Eli Lilly and Company, AbbVie Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, Novo Nordisk A/S, GlaxoSmithKline plc., UCB Pharma, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Ltd, AstraZeneca Plc, Mylan N.V., LEO Pharma A/S, Boehringer Ingelheim GmbH, Alexion Pharmaceuticals Inc., Merck & Co., Inc., Elusys Therapeutics, Inc., Swedish Orphan Biovitrum AB, Samsung Bioepis NL B.V., Biogen Inc., and Theratechnologies Inc.

 Buy now the market research report here: https://www.coherentmarketinsights.com/insight/buy-now/2575

  About Us: Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions.

 What we provide:

Customized Market Research Services

Industry Analysis Services

Business Consulting Services

Market Intelligence Services

Long term Engagement Model

Country Specific Analysis

Request the sample copy of here: https://www.coherentmarketinsights.com/insight/request-sample/2575

 Download the PDF Brochure here: https://www.coherentmarketinsights.com/insight/request-pdf/2575

 Explore CMI Services here Contact Us:

Mr. Shah

Coherent Market Insights Pvt. Ltd.

Address: 1001 4th ave, #3200 Seattle, WA 98154, U.S.

Phone: +1-206-701-6702

Email: sales@coherentmarketinsights.com

  Source: 

https://www.coherentmarketinsights.com/market-insight/u-s-non-oncology-biopharmaceuticals-market-2575

[sriramnanda-blog]

U.S. NON-ONCOLOGY BIOPHARMACEUTICALS MARKET ANALYSIS

Biologics can be defined as molecules derived from living cells such as microorganisms, plants or animal cells and used in the treatment, diagnosis or prevention of diseases. Most of the biologic molecules are very large, complex molecules or mixture of molecules.

Biopharmaceuticals are part of a wider category of therapeutic agents called biologics. Biopharmaceuticals are the substances developed in living systems with the help of biotechnology and are used in therapeutic and diagnostic applications. Non-oncology biopharmaceuticals are the drugs that are used in the treatment of various diseases rather than cancer such as rheumatoid arthritis, psoriatic arthritis, multiple sclerosis, hemophilia, age-related macular degeneration, osteoporosis, and others.

Increasing launches, approvals, and robust pipeline of novel biopharmaceuticals for non-oncology indications .

Frequent approvals, launches, and robust pipeline of novel non-oncology biopharmaceuticals for various indications in the U.S. market is expected to significantly support the U.S. non-oncology biopharmaceuticals market growth.

For instance, in September 2018, Eli Lilly and Company received the U.S. Food and Drug Administration (FDA) approval for its Emgality (galcanezumab-gnlm) 120 mg injection, for the preventive treatment of migraine in adults.

In February 2018, Novartis announced that the U.S. Food and Drug Administration (FDA) approved a label update for its Cosentyx (secukinumab), the first interleukin-17A (IL-17A) inhibitor approved to treat moderate-to-severe plaque psoriasis.

In July 2018, Amgen Inc. and UCB Inc. resubmitted the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for EVENITY (romosozumab), an investigational monoclonal antibody for the treatment of osteoporosis in postmenopausal women at high risk of fracture.

The U.S. non-oncology biopharmaceuticals market size was valued at US$ 116.0 Bn in 2018 and is expected to witness a CAGR of 10.2% during the forecast period (2018 – 2026).

Figure 1. U.S. Non-oncology Biopharmaceuticals Market Share (%), By Product Type, 2018-2026

Source: Coherent Market Insights Analysis (2018)

Increasing mergers and collaborations among key players for development of novel non-oncology biopharmaceuticals is expected to support the market growth

Key players in the market are involved in strategic mergers and collaborations for the development of new biopharmaceutical products and to market them in the U.S. Such strategic mergers and collaborations between key players is expected to support the development of novel products, which in turn is expected to fuel the U.S. non-oncology biopharmaceuticals market growth over the forecast period.

For instance, in 2017, Sanofi S.A. and its vaccines business unit Sanofi Pasteur collaborated with MedImmune, the global biologics research and development arm of AstraZeneca Plc., for the development and commercialization of a monoclonal antibody, namely MEDI8897, for the prevention of Respiratory Syncytial Virus (RSV) associated illness in newborns and infants.

High price of branded biologic products is expected to be a major factor negatively affecting its adoption

According to the report published by the Association for Accessible Medicines in 2018, the annual treatment with Humira comes with a list price of US$ 38,000, and according to the report published by I-Mak.org, between 2012 and 2016, the average spending on Humira per person in U.S. increased from US$ 16,000 to US$ 33,000.

Table 1. Revenue of Top Non-oncology Biopharmaceutical Brands in the U.S.

Source: Coherent Market Insights Analysis (2018)

Market Opportunity

In the recent past, various blockbuster biologics such as Humira and Remicade lost patent in the U.S. market. Furthermore, various other high revenue generating biologics are expected to lose their patents in the near future.

Loss of patent in the U.S. market offers lucrative opportunity to other players for development of its biosimilars. Hence, key players in the market are focused on launch and development of biosimilars of biologic products in the market at affordable price.

For instance, in 2017, Merck & Co., Inc. launched RENFLEXIS (infliximab-abda), a biosimilar of the originator biologic medicine Remicade (infliximab) by Janssen Biotech, Inc. As per the company, RENFLEXIS is introduced in the U.S. at a list price (wholesaler acquisition cost) of US$ 753.39, representing a 35% discount to the current list price of Remicade, which is its reference product.

Market Challenges

High R&D Investments: Developing an IV/injectable biopharmaceutical requires sophisticated infrastructure, skilled scientists, and significant resource investment. Development of a biopharmaceutical product requires extensive clinical research and multiple phases of trials, which is a lengthy and expensive process. These factors are significant barriers for the new players to enter the market.

Sales and Marketing: The U.S. non-oncology biopharmaceuticals market has established market players with strong sales and marketing team. Presence of such strong players in the country creates a big challenge for new players to enter the market and to sustain against such big players.

Physician Acceptance: Physician acceptance of substitutes for well-established products may be a challenge, particularly among indications for which numerous products are available and substitutes do not exhibit high/ better safety profile and/or lower cost.

Key players operating in the U.S. non-oncology biopharmaceuticals market include Sanofi S.A., Pfizer, Inc., Johnson & Johnson, Novartis International AG, Amgen, Inc., Eli Lilly and Company, AbbVie Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, Novo Nordisk A/S, GlaxoSmithKline plc., UCB Pharma, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Ltd, AstraZeneca Plc, Mylan N.V., LEO Pharma A/S, Boehringer Ingelheim GmbH, Alexion Pharmaceuticals Inc., Merck & Co., Inc., Elusys Therapeutics, Inc., Swedish Orphan Biovitrum AB, Samsung Bioepis NL B.V., Biogen Inc., and Theratechnologies Inc.

About Us- Coherent Market Insights is a global market intelligence and consulting organization focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. What we provide: Customized Market Research Services Industry Analysis Services Business Consulting Services Market Intelligence Services Long term Engagement Model Country Specific Analysis Mr. Shah

Coherent Market Insights Pvt.Ltd. Address: 1001 4th Ave, #3200 Seattle, WA 98154, U.S. Phone: +1–206–701–6702 Email: sales@coherentmarketinsights.com

[rohinic123-blog]

Respiratory Virus Infection Drugs Market  Estimated to Record Highest CAGR by 2025

Viral infections disturb either the upper or the lower respiratory tract. These infections can be classified by their causative virus; however, they are clinically classified according to symptoms such as the common cold, croup, and bronchiolitis. Severity of the respiratory virus infection differs broadly. This infection can infect people at any ages; however, the severity is low in adults. The geriatric population and infants with weak immune system are susceptible to severe respiratory virus infections.

Report Overview @

https://www.transparencymarketresearch.com/respiratory-virus-infection-drugs-market.html

Increasing number of patient cases and the rise in the birth rate is anticipated to drive the growth of respiratory virus infection drug market. As per the statistics published by United Nations, Department of Economic and Social Affairs, the global population is projected to reach 8.5 billion by 2030. The surge in the baby boomer population is likely to increase the patient pool of the respiratory virus infection; thereby, increasing the demand for respiratory virus infection drugs over the forecast period. Limited efficacy of the drugs available in the market and the lack of proper in-vitro facilities for conducting research studies for novel treatment alternatives could hamper the growth of the market.

Planning To Lay Down Future Strategy? Request Brochure Of Respiratory Virus Infection Drugs Market

https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=30551

Based on the type of causative virus, the global respiratory virus infection drugs market has been broadly segmented into

Respiratory syncytial viruses (RSV) infectious

Influenza viruses infectious

Parainfluenza viruses infectious

Adenoviruses infectious

Rhinoviruses infectious

In terms of distribution channel, the market has been broadly categorized into

Hospital pharmacies

Drug stores

Retail pharmacies

Clinics

The most common type of respiratory virus infection is RSV, while parainfluenza, adenoviruses, adenoviruses, and rhinoviruses fall into the less common forms. Respiratory syncytial virus infectious segment accounts for a major share of the respiratory virus infection drugs market. As per the statistics published by the World Health Organization, nearly 64 million people are infected and nearly 160,000 deaths caused due to respiratory syncytial virus, annually. The global market for respiratory syncytial virus infection is projected to witness significant growth due to the rise in incidence rate of this infection and birth rate.

To Obtain All-Inclusive Information On Forecast Analysis Of Respiratory Virus Infection Drugs Market , Request A Discount

https://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=30551

Emphasis on establishing hospitals as primary care providers, hospital pharmacies segment is expected to be the most lucrative distribution channel. Numerous state-of-art hospital chains worldwide, owing to the rising government investments, and improving accessibility to medicines at reasonable prices are some factors that can help hospital pharmacy segment to retain its strong market position during the forecast period.

Geographically, the global respiratory virus infection drugs market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. According to the statistics published by the U.S., Department of Health & Human Services, approximately 50% of the children infected with RSV were under two-years of the age, globally. North America and Europe are expected to hold the largest share of market due to high awareness and easily available diagnostic tests. Asia Pacific is expected to be the fastest growing market over the forecast period. Lack of appropriate population-based studies in developing countries could challenge the assessment of respiratory-related virus infections.

Request For Covid19 Impact Analysis –

https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=30551

Key players operating in the global respiratory virus infection drugs market include AstraZeneca, AbbVie, Ablynx NV, ADMA Biologics, Alnylam Pharmaceuticals, Ark Biosciences, ImmunoVaccine Technologies, Aviragen Therapeutics, Boehringer Ingelheim, Bavarian Nordic, Gilead Sciences, Johnson & Johnson, Kyowa Hakko Kirin, Mymetics Corporation, GlaxoSmithKline plc., Teva Pharmaceutical, and Vaxart.

The report offers a comprehensive evaluation of the market. It does so via in-depth qualitative insights, historical data, and verifiable projections about market size. The projections featured in the report have been derived using proven research methodologies and assumptions. By doing so, the research report serves as a repository of analysis and information for every facet of the market, including but not limited to: Regional markets, technology, types, and applications.

More Trending Reports by Transparency Market Research –

Biosimilars Market -

https://www.prnewswire.com/news-releases/global-biosimilars-market-to-reach-us-21-1-bn-by-2027--role-in-reducing-cost-of-cancer-treatment-key-to-growth-transparency-market-research-301008265.html

Read our Case study at

https://www.transparencymarketresearch.com/casestudies/innovative-medical-device-manufacturing-start-up

[nitasonwane]

Respiratory Syncytial Virus Therapeutics Market Competitive Analysis, Size, Growth Rate, Key Company Share, Outlook by 2027

The global respiratory syncytial virus (RSV) therapeutics market size is estimated to showcase potential growth owing to its increasing adoption against the prevention and treatment of the disease, observes Fortune Business Insights™ in an upcoming report, titled, “Respiratory Syncytial Virus (RSV) Therapeutics Market Size, Share & COVID-19 Impact Analysis, By Drug Class (Prophylaxis and Treatment), By End-user (Hospital Pharmacy, Retail Pharmacy, and Online Pharmacy) and Regional Forecast, 2020-2027.” The respiratory syncytial virus (RSV) therapeutics market stood at USD 1,111.3 million in 2019. It is projected to grow from USD 609.2 million in 2020 to USD 4,003.4 million in 2027 at a CAGR of 30.9% in the forecast period.

Get Sample Report On Global Respiratory Syncytial Virus (RSV) Therapeutics Market: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/respiratory-syncytial-virus-rsv-therapeutics-market-104668

High Production Scale to Hinder Growth Opportunities in Global Pharmaceutical Space

The COVID-19 contagion is expected to drive the global pharmaceutical industry. Enterprises across the world along with governments from several nations are contributing to the development and distribution of the vaccine. However, the scale at which the production is assumed to take place is a major challenge for most of the renowned players. At Fortune Business Insights™, we are providing actionable insights by closely studying multiple aspects of the current scenario. We are also offering firsthand information on various market trends through our comprehensive research reports.

New Product Launches from Key Players Helped Prophylaxis Segment Hold Largest Share In 2019

Based on drug class, the prophylaxis segment led the market with the largest share in 2019. Potential approvals and launch of maternal vaccines by companies including Pfizer and GSK are estimated to help the segment further dominate the market during the forecast timeframe. Based on end-user, the hospital pharmacy segment dominated the global market owing to the high demand for healthcare professionals for the existing treatment and prevention options.

[sandlerresearch]

Respiratory Syncytial Virus: Opportunity Analysis and Forecasts to 2028 published on

http://www.sandlerresearch.org/respiratory-syncytial-virus-opportunity-analysis-and-forecasts-to-2028.html

Respiratory Syncytial Virus: Opportunity Analysis and Forecasts to 2028

Respiratory Syncytial Virus: Opportunity Analysis and Forecasts to 2028

Summary

Human respiratory syncytial virus (RSV) is an enveloped, single-stranded, negative-sense RNA orthopneumovirus belonging to the family of Paramyxoviridae. The virus was discovered in 1956, first as an isolate from a laboratory chimpanzee displaying symptoms of the common cold, and later from infants suffering from respiratory disease.

The most common clinical scenario for RSV is an upper respiratory tract infection which is typically mild and self-limiting. However, RSV is the leading cause of lower respiratory tract infections (LRTIs) in infants, with a peak age of hospitalization between 2-3 months of age. Severe respiratory disease can manifest as bronchiolitis and pneumonia, which can progress to respiratory failure or death in rare occasions. RSV is also an important cause of hospitalizations and deaths in elderly adults.

The burden of RSV-associated illness is well known; however, challenges stemming from both product and clinical trial design have resulted in several high-profile product failures across all classes of agents including antivirals and prophylactic vaccines and antibodies. Further, the RSV market has seen contraction as the only approved prophylactic antibody, AbbVie and AstraZeneca’s Synagis (palivizumab), received an updated recommendation from the American Academy of Pediatrics (AAP) in 2014 for a more narrow population than the antibody is labeled for (i.e., pediatric patients at increased risk of hospitalization due to RSV). These difficulties have limited options for patients currently at risk for complications due to RSV; however, they have driven strong developer interest in addressing RSV across multiple therapeutic avenues.

Key Questions Answered

– How will the RSV therapeutic market landscape in the 7MM (US, France, Germany, Italy, Spain, UK, Japan) change from 2018-2028? – What are the most promising late-stage pipeline drugs for RSV? – How do the clinical and commercial attributes of late-stage pipeline therapies compare with one another, and against existing treatment options? – What are the remaining unmet needs in RSV treatment management? – What drivers and barriers will affect RSV therapeutics sales in the 7MM over the forecast period?

Scope

– Overview of RSV, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies. – Topline RSV market revenue from 2018-2028. Annual cost of therapy (ACOT) and major pipeline product sales in this forecast period are included. – Key topics covered include current treatment and prophylactic options, unmet needs and opportunities, and the drivers and barriers affecting RSV therapeutics sales in the 7MM. – Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products. – Analysis of the current and future market competition in the global RSV therapeutics and prophylactics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to buy

The report will enable you to – – Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline. – Develop business strategies by understanding the trends shaping and driving the global RSV market. – Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the RSV therapeutics market in the future. – Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. – Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. – Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

[sapanas]

RSV Diagnostics Market Outlook and Growth Stance Forecast Through 2023

RSV Diagnostics Market Highlights

The latest report by Market Research Future (MRFR) states that the Respiratory Syncytial Virus (RSV) market is all set to gain substantial traction by accruing gigantic revenues by 2023. In addition, it is on track to surge at a CAGR of 10.4 % during the forecast period (2018–2023).

RSV Diagnostics Market Drivers and Top Restraints

The document named “Reducing Neonatal Mortality and Morbidity in Latin America And the Caribbean, An Interagency Strategic Consensus” states that almost 400,000 children under the age of five die due to infections that could have been prevented. This has attracted the focus of various health agencies that are striving to get a hold of the issue. For instance, Latin American Center for Perinatology and Pan America Health Organization (PAHO) have diverted their focus in the direction of educating the parents to fight against possible infections, promoting the growth of the RSV diagnostics market in the process.

The rising incidence rate of respiratory infections has done wonders for the market and is bound to surge at a significant rate in the coming years. with the growth in the incidences of chronic diseases around the world, there is bound to be an increase in the case of respiratory infections. This is going to have a definite positive impact on the demand for testing of infectious diseases like RSV. The deaths among neonates owing to these infections can be prevented when timely diagnosis and subsequent treatment is provided. Thus, the growing awareness regarding this factor is set to enhance the growth of the RSV diagnostics market in the years ahead.

The boost in the number of product launches across the globe will be one of the primary reasons fueling the growth of the respiratory syncytial virus diagnostics market in the forthcoming years. On that note, various diagnostics companies are keen on expanding their revenue with the development and introduction of the latest RSV diagnostics products in the market. These sophisticated diagnostic products are known to be highly efficient and reduce the time needed for the diagnosis.

The Rising Number of OEMs to be the Key Trend in the Global Market

The growth in the number of original equipment manufacturers (OEMs) is on its way to become a popular trend in the worldwide RSV diagnostics market in the near future. OEMs like Thermo Fisher Scientific and Sekisui Diagnostics are one of the leading manufacturers that offer RSV diagnostics.

There has been a rise in the number of combination products like drug delivery and smart devices, which is prompting the OEMs to work in conjunction with the contract manufacturing organizations (CMOs), making way for a number of new companies to gain entry into the market. As a result, there has been an increase in the product range required for diagnosing RSV.

RSV Diagnostics Market Segmentation

The global RSV diagnostics market has been segmented based on product, method, and end-user.

Depending on the type of product, the market has been classified into kits and assays, instruments, and other products.

Method-wise, the global RSV diagnostics market has been considered for molecular diagnostics, rapid antigen detection test, gel microdroplets, flow cytometry, and others. Furthermore, the rapid antigen detection tests are sub-segmented into enzyme-linked immunosorbent assays, immunofluorescence assays, and other rapid antigen detection tests. The other type of rapid antigen detection tests can be segmented into chromatographic immunoassays and optical immunoassays.

The end-users mentioned in the report include hospitals and clinics, clinical laboratories, home care, and others.

RSV Diagnostics Market Regional Outlook

The global RSV diagnostics market is segmented into the regional markets of the Americas, Asia Pacific, Europe, as well as the Middle East & Africa.

The Americas will be the most lucrative market for RSV diagnostics on account of the rising incidences of RSV, growing healthcare expenditure and technological advancements in molecular diagnostics. As per the Centers for Disease Control and Prevention, over 57,000 children younger than five years old are hospitalized owing to RSV infection every year, in the United States (U.S). In order to bring down this abysmal number, various initiatives and programs are being introduced in the region, which means that the market will be doing excellent business in the region in the years to come.

Meanwhile, Europe has landed the second spot in the global RSV diagnostics market, with factors like increasing automation in vitro diagnostics, rising occurrence of RSV diseases, and surging funding offered by the government backing the said growth. Considering the current status of the region, the data furnished by the University of Oxford states that more than 30,000 babies and children less than five years of age are expected to be hospitalized every year owing to RSV.

The RSV diagnostics market in Asia Pacific can be broken down into smaller markets in the countries of India, Japan, China, Republic of Korea, Australia and the rest of the region. The regional market is touted to be the fastest-growing globally as a result of the rise in the infectious disease which includes the RSV infection. Also, the increasing healthcare expenditure coupled with the surge in the demand for RSV disease diagnosis has taken the market to higher levels in the past few years. In addition, countries like India, China, and Japan are deemed to be growing at the fastest rate in the region with the expanding healthcare systems along with the growing government initiatives backing up these markets.

Showcasing a rather sluggish growth rate in the global market is the region of the Middle East and Africa, which despite various restraints holds immense potential. The market shows promise, with the support of various factors including the increasing awareness and high investments by private industry participants combined with the increasing incidences of RSV in children in the region.

Get Premium Research Report, Inclusive of COVID-19 Impact Analysis, Find more information @ https://www.marketresearchfuture.com/reports/rsv-diagnostics-market-6217

RSV Diagnostics Market Key Vendors

Bio-Rad Laboratories Inc., Abbott, F. Hoffman-La Roche Ltd., Danaher Corporation, Quest Diagnostics, Biocartis, Luminex, Hologic, Fast Track Diagnostics, Biomerieux, Becton, Dickinson, and Company (BD), Alere, Inc., Quidel Corporation, Thermo Fisher Scientific are among some of the top most companies in the RSV diagnostics market.

RSV Diagnostics Industry Latest News

May 2019: SpeeDx Pty. Ltd. has gotten the clearance from the Australian Therapeutic Goods Administration (TGA) of their PlexPCR RespiVirus test. It makes use of the PlexPCR technology for detecting 11 types of pathogens known for causing viral respiratory-illnesses. In addition, this test also lets the laboratories process a greater number of samples in a limited period of shift compared to a conventional in-house test.

[soumyafwr]

https://articlepedia.xyz/global-respiratory-syncytial-virus-rsv-therapeutics-market-size-share-and-forecast-2031/

Respiratory Syncytial Virus (RSV) Therapeutics Market 

[amanjadejablog]

Respiratory Syncytial Virus (RSV) Therapeutics Market Report | What are the key challenges to the Market growth?

“The latest report, Respiratory Syncytial Virus (RSV) Therapeutics  market attempts to explain as well as understand the buying pattern to help companies design a marketing strategy that can attract more buyers. The approach empowers stakeholders to target audience more accurately and reap highest profits. The product research carried out during the study of the Respiratory Syncytial Virus (RSV) Therapeutics market for the forecast period, 2019 to 2025 aims at helping product owners tweak their products or services according to the taste customers.

Get a FREE Sample PDF Report: https://www.marketgrowthinsight.com/sample/18893

Apart from this, the valuable document weighs upon the performance of the industry on the basis of a product service, end-use, geography and end customer.

When studying the major drivers a conscious effort is made to assess the rise in the product demand, changes in regulatory policies and fluctuating prices of the raw material. Importantly, the study quantifies the industry share occupied by the prominent vendors and offers an extensive view of the growing investment pocket in the Respiratory Syncytial Virus (RSV) Therapeutics industry worldwide.

Detailed evaluation of various aspects with respect to the geography for the estimated period forms an important part of the research.

A quick look at the industry trends and opportunities

The market opportunity analysis offered in the market intelligence report measures various intangible factors such as gross margin, profit, demand and supply, distribution channel and spending power of the customers. Importantly, the study classifies the industry into an array of segments based on product type, application and consumer preference 

Make an Inquiry of Respiratory Syncytial Virus (RSV) Therapeutics market Report: https://www.marketgrowthinsight.com/inquiry/18893

The report also presents the market competitive landscape and a corresponding detailed analysis of the major vendor/key players in the market.

The key players covered in this report: 

• The major manufacturers covered in this report Roche AstraZeneca Merck AbbVie Valeant Pharmaceuticals GlaxoSmithKline ReViral Gilead Sciences Teva Pharmaceutical

• Geographically, this report studies the top producers and consumers, focuses on product capacity, production, value, consumption, market share and growth opportunity in these key regions, covering North America Europe China Japan Southeast Asia India

• On the basis of product, this report displays the production, revenue, price, market share and growth rate of each type, primarily split into Palivizumab Ribavirin Others

• On the basis of the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including Hospital Pharmacies Drug Stores Retail Pharmacies Others

• Key Stakeholders Respiratory Syncytial Virus (RSV) Therapeutics Manufacturers Respiratory Syncytial Virus (RSV) Therapeutics Distributors/Traders/Wholesalers Respiratory Syncytial Virus (RSV) Therapeutics Subcomponent Manufacturers Industry Association Downstream Vendors

This report studies the global Respiratory Syncytial Virus (RSV) Therapeutics market status and forecast, categorizes the global Respiratory Syncytial Virus (RSV) Therapeutics market size (value & volume) by manufacturers, type, application, and region. This report focuses on the top manufacturers in North America, Europe, Japan, China, and other regions (India, Southeast Asia).

A thorough evaluation of the key driving forces proves beneficial in understanding the manner in which major vendors communicate with their current prospects and existing customers. Detailed data on the restraining factors aid companies and individual lowering the risks. It does so by revealing which opportunities will result in generating more profits.

Purchase Respiratory Syncytial Virus (RSV) Therapeutics Market Research Report: https://www.marketgrowthinsight.com/checkout/18893

The Research Provides Answers to the Following Key Questions:

What is the size of occupied by the prominent leaders for the forecast period, 2019 to 2025? What will be the share and the growth rate of the Respiratory Syncytial Virus (RSV) Therapeutics market during the forecast period?

Which companies are dominating the competitive landscape across different region and what strategies have they applied to gain a competitive edge?

What are the major factors responsible for the growth of the Respiratory Syncytial Virus (RSV) Therapeutics market across the different regions?

What are the challenges faced by the companies operating in the Respiratory Syncytial Virus (RSV) Therapeutics market?

What are the future prospects for the Respiratory Syncytial Virus (RSV) Therapeutics market industry in the coming years?

Which trends are likely to contribute to the development rate of the Respiratory Syncytial Virus (RSV) Therapeutics industry during the forecast period, 2019 to 2025?

What are the future prospects of the Respiratory Syncytial Virus (RSV) Therapeutics industry for the forecast period, 2019 to 2025? 

About us : Market Growth Insight, is a one stop solution for market research reports in various business categories. We are serving 100+ clients with 10000+ diverse industry reports and our reports are developed to simplify strategic decision making, on the basis of comprehensive and in-depth significant information, established through wide ranging analysis and latest industry trends. Contact us : 502, Sai Radhe, Kenedy Road, Behind Hotel Sheraton Grand, Near Pune Station, Pune-411001, sales@marketgrowthinsight.com + 91 8956 049 020

Connect With Us : Twitter | Linkedin | Facebook | Google+

  from WordPress http://bit.ly/2wDO5OY via IFTTT